Guidance
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
In April 2023, we updated section 1 to reflect the current format of NICE guidance. We also added some text to the clinical evidence section to summarise new clinical evidence reviewed. NICE’s recommendations for UrgoStart remain unchanged. More details are in the review decision. New text is marked [2023].
Implementation
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
This guidance replaces NICE medtech innovation briefing on UrgoStart for chronic wounds (MIB82).